Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: David Bogdanoff who wrote (1381)	5/20/1998 9:49:00 PM
From: arnie h	Read Replies (1) \| Respond to of 2173

David: Thank you too for responding to my question about body tolerance. I used the cancer example as a clear case of a specific mechanism being used by cells to get around their downfall. I was really wondering whether specific mechanisms could be conceived that would lead to weakening response to pramlinitide. Your point about the body maintaining equilibrium is well taken, short of specific biomechanical reactions. At some point, we'll have a better feel when the ongoing trial results are in. Thanks again, Anrie